We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 8, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Humana Inc. (HUM - Free Report) , Cintas Corp. (CTAS - Free Report) , Biogen Inc. (BIIB - Free Report) , Royal Caribbean Cruises Ltd. (RCL - Free Report) and Markel Group Inc. (MKL - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Humana, Cintas and Biogen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Humana Inc., Cintas Corp. and Biogen Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Humana have declined -8.9% over the year-to-date period against the Medical - HMOs industry's decline of -10.8%. The companies escalating operating costs are affecting profits. A debt-laden balance sheet induces a rise in interest expenses. As such, the stock warrants a cautious stance.
Nevertheless, Humana's Medicaid business benefits from several contract wins and renewals thereby contributing to the top line. Strategic buyouts and alliances place it well for growth in the future.
Solid contributions from the Insurance and CenterWell segments bode well. Management estimates adjusted 2023 EPS to be at least $28.25, reflecting minimum growth of 12% year over year. It has been deploying excess capital through share buybacks and dividend payments on balance sheet strength.
Cintas' shares have outperformed the Zacks Uniform and Related industry over the year-to-date period (+10.6% vs. +9.2%). Strong segmental performances have been aiding the company. Increased productivity level and new product launches are boosting the Uniform Rental and Facility Services segment's performances.
Strength in the health and wellness businesses and high customer retention levels are driving the growth of the First Aid and Safety Services segment. The company's focus on enhancement of its product portfolio holds promise. Cintas' efforts to reward shareholders are impressive.
However, the rising cost of sales, and increasing selling and administrative expenses pose a threat to the company's bottom line. High tax rate is an added concern for Cintas. Also, foreign currency headwinds are weighing on the company's top line.
Shares of Biogen have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+26.8% vs. -10.8%). The company's potential new products like Leqembi in Alzheimer's disease, Qalsody in ALS and zuranolone in depression can help revive growth. With Leqembi receiving traditional approval and broader CMS coverage in the United States, it has the potential to generate blockbuster sales.
Biogen is exploring both early to mid-stage assets and late-stage assets to build its pipeline. However, Biogen's has a high-risk pipeline. Sales of Leqembi are expected to be slow in 2023.
It is also facing multiple challenges at present like the generic erosion of Tecfidera, competitive pressure for Spinraza, declining profit share of Rituxan in the United States and the failure of Aduhelm. Most of its key drugs are facing declining sales.
Other noteworthy reports we are featuring today include Royal Caribbean Cruises Ltd. and Markel Group Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group
For Immediate Release
Chicago, IL – September 8, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Humana Inc. (HUM - Free Report) , Cintas Corp. (CTAS - Free Report) , Biogen Inc. (BIIB - Free Report) , Royal Caribbean Cruises Ltd. (RCL - Free Report) and Markel Group Inc. (MKL - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Humana, Cintas and Biogen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Humana Inc., Cintas Corp. and Biogen Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Humana have declined -8.9% over the year-to-date period against the Medical - HMOs industry's decline of -10.8%. The companies escalating operating costs are affecting profits. A debt-laden balance sheet induces a rise in interest expenses. As such, the stock warrants a cautious stance.
Nevertheless, Humana's Medicaid business benefits from several contract wins and renewals thereby contributing to the top line. Strategic buyouts and alliances place it well for growth in the future.
Solid contributions from the Insurance and CenterWell segments bode well. Management estimates adjusted 2023 EPS to be at least $28.25, reflecting minimum growth of 12% year over year. It has been deploying excess capital through share buybacks and dividend payments on balance sheet strength.
(You can read the full research report on Humana here >>>)
Cintas' shares have outperformed the Zacks Uniform and Related industry over the year-to-date period (+10.6% vs. +9.2%). Strong segmental performances have been aiding the company. Increased productivity level and new product launches are boosting the Uniform Rental and Facility Services segment's performances.
Strength in the health and wellness businesses and high customer retention levels are driving the growth of the First Aid and Safety Services segment. The company's focus on enhancement of its product portfolio holds promise. Cintas' efforts to reward shareholders are impressive.
However, the rising cost of sales, and increasing selling and administrative expenses pose a threat to the company's bottom line. High tax rate is an added concern for Cintas. Also, foreign currency headwinds are weighing on the company's top line.
(You can read the full research report on Cintas here >>>)
Shares of Biogen have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+26.8% vs. -10.8%). The company's potential new products like Leqembi in Alzheimer's disease, Qalsody in ALS and zuranolone in depression can help revive growth. With Leqembi receiving traditional approval and broader CMS coverage in the United States, it has the potential to generate blockbuster sales.
Biogen is exploring both early to mid-stage assets and late-stage assets to build its pipeline. However, Biogen's has a high-risk pipeline. Sales of Leqembi are expected to be slow in 2023.
It is also facing multiple challenges at present like the generic erosion of Tecfidera, competitive pressure for Spinraza, declining profit share of Rituxan in the United States and the failure of Aduhelm. Most of its key drugs are facing declining sales.
(You can read the full research report on Biogen here >>>)
Other noteworthy reports we are featuring today include Royal Caribbean Cruises Ltd. and Markel Group Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.